Orexigen halts work on diet pill in US

Narachi said the company also was discouraged by the FDA's plan to convene an expert advisory panel sometime in 2012 to discuss wider concerns over the risk of approving new weight–loss drugs that have sidetracked two other experimental diet pills in …
See all stories on this topic »